The $1.6 Billion the MSOs Owe the IRS — And Why They're Not Paying

The biggest story in cannabis right now isn't a recall, a lawsuit, or a state legalization vote. It's a number. One point six billion dollars. That's how much the largest American multistate cannabis operators collectively owe the Internal Revenue Service in unpaid federal taxes, according to the companies' own public filings as of March 2026.

This isn't tax evasion in the criminal sense. The MSOs aren't hiding the money. They're disclosing it, openly, in SEC filings and quarterly earnings reports. They're telling shareholders and the federal government, in writing, that they owe the IRS hundreds of millions of dollars each — and they're not going to pay. Not yet. Maybe not ever.

It's the most audacious financial gambit in the modern American economy, and almost no one outside cannabis trade press is covering it. Here's what's actually happening.

The 280E Problem That Created This Mess

To understand why MSOs are sitting on $1.6 billion in unpaid taxes, you need to understand Section 280E of the Internal Revenue Code.

Passed in 1982 in response to a Tax Court case involving a convicted cocaine trafficker, Section 280E says that any business "trafficking in controlled substances" prohibited by federal law cannot deduct ordinary business expenses for federal tax purposes. Rent. Salaries. Marketing. Utilities. Equipment. None of it deductible.

In a normal business, you pay taxes on profit — revenue minus expenses. Under 280E, cannabis companies pay federal taxes on something close to gross revenue, because they can only deduct cost of goods sold. The effective federal tax rate for a state-legal cannabis business often runs 60–80% or higher. That's not hyperbole. That's the math.

For a decade, the industry has been screaming about 280E. They've lobbied. They've sued. They've watched bills die in Congress. And meanwhile, every quarter, the tax bill comes due and they have to pay it — out of cash flow, out of capital raises, out of debt.

Until they decided, collectively, to stop paying.

The Strategy: Withhold Now, Litigate Later

The non-payment isn't accidental. It's a strategy. The MSOs are betting that Section 280E will eventually be invalidated — either through federal cannabis rescheduling, through litigation that's already in motion, or through Congressional action — and that when it is, they'll be entitled to retroactive refunds.

The leading plaintiffs in the federal case challenging 280E are the same companies whose names appear on the largest unpaid tax balances. Ascend Wellness. Curaleaf. TerrAscend. The argument is essentially: if 280E shouldn't have applied to us all along, we shouldn't have paid those taxes in the first place. We're going to stop paying them now, on the theory that we'll eventually win the legal challenge and the IRS will refund what we already paid plus what we didn't pay.

It's a high-stakes bet. If the litigation fails, or rescheduling stalls, or Congress doesn't act, the IRS will eventually move to collect — with penalties, with interest, with potential liens against company assets. For some MSOs, the unpaid balance now exceeds their cash on hand. A losing court ruling could trigger immediate bankruptcy filings.

For others, the strategy has already started to crack. The Cannabist Co., a major MSO that filed for bankruptcy in March 2026, listed the IRS as one of its largest creditors, owing roughly $270 million in combined back taxes and lender debt.

Who Owes What

The exact distribution of the $1.6 billion is staggered across roughly a dozen companies, but a handful of operators account for the bulk of the balance.

Curaleaf Holdings, by most analyst estimates, carries the largest single unpaid tax balance, in the high nine figures. Trulieve, Cresco Labs, Green Thumb Industries, and Verano each carry balances in the low to mid nine figures. Ascend Wellness and TerrAscend, the most public proponents of the litigation strategy, are also among the largest delinquent payers.

These figures are not secret. They appear in 10-Q and 10-K filings, in management discussion sections, and in auditor going-concern disclosures. Anyone with access to SEC EDGAR can read them. The mainstream financial press has barely touched the story.

The IRS Is Watching

It would be easy to assume the IRS is asleep at the switch on this. They're not. The agency has assigned dedicated examiners to the cannabis sector. They've issued industry-specific guidance. They've conducted hundreds of audits.

What they have not done — yet — is move aggressively to collect from the MSOs. The reasons are pragmatic. The companies are publicly disclosing the debt. They're filing returns. They're not concealing income. Tax-collection priorities at the federal level skew toward enforcement against actors who hide what they owe, not actors who admit it openly while contesting the underlying liability.

But the patience is not infinite. IRS commissioners have signaled in congressional testimony that the cannabis sector's collective unpaid balance is on the agency's radar. Tax liens have begun appearing in some jurisdictions. Bankruptcy filings now routinely list the IRS as a senior creditor. The window for the litigation strategy to pay off is closing faster than the MSOs would like to admit.

What Happens If the Strategy Fails

There are three scenarios for how this resolves.

Scenario one: Federal rescheduling moves cannabis from Schedule I to Schedule III. Section 280E only applies to Schedule I and II controlled substances. A reschedule to III would eliminate 280E exposure prospectively and arguably support the MSO position that the tax should never have applied to legitimate state-licensed operations. This is the scenario the MSOs are betting on. The DEA's rescheduling process has been in motion for years and was nearing finalization in early 2026, but federal regulatory processes are notoriously susceptible to political delay.

Scenario two: The federal litigation succeeds. The MSOs win their challenge to 280E in court, the IRS is ordered to refund overpayments, and the unpaid balances are discharged. This is a longer shot. Federal courts have not historically been receptive to constitutional challenges from federally illegal businesses, and the government's defense — that the law is the law and Congress writes the tax code — is hard to beat.

Scenario three: Both fail. Rescheduling stalls or gets reversed under a different administration. The litigation loses on the merits or runs out of appeals. The IRS moves to collect. In this scenario, the MSOs face a generational financial crisis. Multiple companies would face bankruptcy. Asset sales would accelerate. Lender recoveries would be ahead of tax claims in some structures but behind in others, leading to years of litigation between creditors and the federal government over priority.

What This Means for the Rest of the Industry

If you're a small operator paying your 280E liability quarterly, watching the MSOs sit on unpaid balances bigger than your entire annual revenue is a particular kind of insult. You're funding the same federal government that's collecting your money while another company down the road simply chooses not to pay. The asymmetry is grotesque.

There's also a competitive dynamic. MSOs that are not paying their taxes have, in effect, an interest-free loan from the federal government — money they can deploy into expansion, marketing, lobbying, and acquisitions while smaller competitors fund their own operations out of after-tax cash. It is, in functional terms, a subsidy to the largest operators, paid for by the disciplined compliance of the smallest.

It is also a ticking bomb. When the resolution comes — whatever form it takes — the shockwaves will hit every part of the industry. Distressed MSO assets will hit the market. Receivership filings will create opportunities for cash-rich buyers. State regulators will face awkward questions about why they licensed operators with rapidly growing federal tax delinquencies.

What Consumers Should Know

The product on dispensary shelves doesn't change because of any of this. The flower is still flower. The vape is still a vape. But the price you pay for it reflects the financial structure of the company that produced it. Companies carrying enormous unpaid tax balances have to fund their operations somehow, and ultimately, that funding comes from your purchase.

When the MSOs eventually have to settle up — and they will, one way or another — the cost of that settlement is going to be passed somewhere. Either to investors through equity dilution, to creditors through restructured debt, or to consumers through sustained high prices. There's no scenario where the bill simply disappears.

Cannabis was supposed to be the industry that did things differently. Pay workers fairly. Repair the harms of prohibition. Operate transparently. Instead, we have an industry where the largest companies have collectively decided that paying federal taxes is optional and the IRS is a creditor to be managed rather than an authority to be obeyed.

It's a uniquely cannabis story. It's also a uniquely American one.

---

Cannabis.exposed tracks MSO financials, regulatory actions, and tax litigation. Subscribe for ongoing coverage.

Internal links:

• The MSO Cartel: Inside the Price-Fixing Lawsuit →
• The $6 Billion Debt Wall →
• What Is Section 280E and Why Is It Killing Cannabis Companies →